Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan.

Kenichi Ishizawa,Michinori Ogura,Dai Maruyama,Yasunobu Abe,Kiyoshi Ando,Koji Izutsu,Yasuhito Terui,Imaizumi Yoshitaka,Noriko Fukuhara,Toshiki Uchida,Ilseung Choi,Ken Ohmachi,Go Yamamoto,Kensei Tobinai

Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan.

2016

Kenichi Ishizawa
Michinori Ogura
Dai Maruyama
Yasunobu Abe
Kiyoshi Ando
Koji Izutsu
Yasuhito Terui
Imaizumi Yoshitaka
Noriko Fukuhara
Toshiki Uchida
Ilseung Choi
Ken Ohmachi
Go Yamamoto
Kensei Tobinai

e19050Background: No clinical evidence is available about the bendamustine and rituximab (BR) regimen as the first-line treatment of indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymp...

Keywords:

Cancer research
Rituximab
Bendamustine
B-Cell Non-Hodgkin Lymphoma
Medicine
Mantle cell lymphoma
Pathology
Cell
Oncology
clinical evidence
Lymphoma
Internal medicine
Regimen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations